Literature DB >> 33639890

Monoclonal gammopathy of renal significance (MGRS)-related AL amyloidosis complicated by amyloid myopathy: a case report.

Erina Ono1, Akira Ishii2, Yoshiaki Higashi1, Natsuko Koita3, Takashi Ayaki3, Katsuya Tanigaki1, Shunsuke Takayanagi1, Naoya Kondo1, Kaoru Sakai1, Shuichiro Endo1, Hideki Yokoi1, Takeshi Matsubara1, Sachiko Minamiguchi4, Ichizo Nishino5, Ryosuke Takahashi3, Motoko Yanagita1.   

Abstract

BACKGROUND: Lately, monoclonal gammopathy of renal significance (MGRS) has been defined as a group of renal disorders that are strongly associated with monoclonal protein, including amyloid immunoglobulin light chain (AL) amyloidosis. Amyloid myopathy is rare (1.5% of all patients with amyloidosis) and the prognosis is poor. Furthermore, only approximately 20% of patients with amyloid myopathy are reported to have renal involvement, indicating a lack of data in the literature. CASE
PRESENTATION: Here, we report a rare case of MGRS-related AL amyloidosis complicated by amyloid myopathy that presented with muscle weakness in the upper and lower limbs, neck and fingers, and nephrotic syndrome. Blood, urine, and bone marrow examination revealed monoclonal gammopathy of undetermined significance (MGUS) (Bence Jones protein-lambda). Muscle biopsy of the vastus lateralis muscle demonstrated amyloid proteins in the sarcolemma and in the blood vessel walls on Congo red staining, suggesting amyloid myopathy, and tiny inclusions in fibers on modified Gomori trichrome stain. Although we thought they were reminiscent of nemaline bodies, we could not confirm the nature of this structure. Renal biopsy demonstrated amyloid proteins in the mesangial region, part of the capillary walls, and the blood vessel walls on direct fast scarlet staining. As these amyloid proteins were positive for p-component staining and negative for amyloid A staining, β2-microglobulin, and pre-albumin, and as lambda light chains were positive in the mesangial region, we diagnosed the patient with MGRS-related AL amyloidosis. Although he was treated with melphalan and dexamethasone, his symptoms did not improve.
CONCLUSIONS: AL amyloidosis involving the kidneys and muscles has a poor prognosis, and a delayed diagnosis of amyloid myopathy is common because of its rarity and frequent misdiagnosis, which increases organ function deterioration. Therefore, early detection, therapeutic intervention, and careful follow-up are crucial.

Entities:  

Keywords:  Amyloid myopathy; Amyloidosis; Monoclonal gammopathy of renal significance; Monoclonal gammopathy of undetermined significance; Sporadic late-onset nemaline myopathy

Mesh:

Year:  2021        PMID: 33639890      PMCID: PMC7916314          DOI: 10.1186/s12882-021-02272-7

Source DB:  PubMed          Journal:  BMC Nephrol        ISSN: 1471-2369            Impact factor:   2.388


  25 in total

Review 1.  Dangerous small B-cell clones.

Authors:  Giampaolo Merlini; Marvin J Stone
Journal:  Blood       Date:  2006-06-22       Impact factor: 22.113

2.  Amyloid myopathy masquerading as polymyositis.

Authors:  L A Mandl; R D Folkerth; M A Pick; M E Weinblatt; E M Gravallese
Journal:  J Rheumatol       Date:  2000-04       Impact factor: 4.666

3.  Sporadic late-onset nemaline myopathy: clinical, pathology and imaging findings in a single center cohort.

Authors:  Mauro Monforte; Guido Primiano; Gabriella Silvestri; Massimiliano Mirabella; Marco Luigetti; Cristina Cuccagna; Enzo Ricci; Serenella Servidei; Giorgio Tasca
Journal:  J Neurol       Date:  2018-01-22       Impact factor: 4.849

4.  Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements.

Authors:  Shaji Kumar; Angela Dispenzieri; Martha Q Lacy; Suzanne R Hayman; Francis K Buadi; Colin Colby; Kristina Laumann; Steve R Zeldenrust; Nelson Leung; David Dingli; Philip R Greipp; John A Lust; Stephen J Russell; Robert A Kyle; S Vincent Rajkumar; Morie A Gertz
Journal:  J Clin Oncol       Date:  2012-02-13       Impact factor: 44.544

Review 5.  Diagnosis of monoclonal gammopathy of renal significance.

Authors:  Frank Bridoux; Nelson Leung; Colin A Hutchison; Guy Touchard; Sanjeev Sethi; Jean-Paul Fermand; Maria M Picken; Guillermo A Herrera; Efstathios Kastritis; Giampaolo Merlini; Murielle Roussel; Fernando C Fervenza; Angela Dispenzieri; Robert A Kyle; Samih H Nasr
Journal:  Kidney Int       Date:  2015-01-21       Impact factor: 10.612

6.  Paraprotein-Related Kidney Disease: Diagnosing and Treating Monoclonal Gammopathy of Renal Significance.

Authors:  Mitchell H Rosner; Amaka Edeani; Motoko Yanagita; Ilya G Glezerman; Nelson Leung
Journal:  Clin J Am Soc Nephrol       Date:  2016-08-15       Impact factor: 8.237

7.  Amyloid myopathy: characteristic features of a still underdiagnosed disease.

Authors:  John E Chapin; Mario Kornfeld; Alexis Harris
Journal:  Muscle Nerve       Date:  2005-02       Impact factor: 3.217

8.  Characterization of isolated amyloid myopathy.

Authors:  T Liewluck; M Milone
Journal:  Eur J Neurol       Date:  2017-10-05       Impact factor: 6.089

Review 9.  Sporadic late-onset nemaline myopathy: clinico-pathological characteristics and review of 76 cases.

Authors:  Lukas J Schnitzler; Tobias Schreckenbach; Aleksandra Nadaj-Pakleza; Werner Stenzel; Elisabeth J Rushing; Philip Van Damme; Andreas Ferbert; Susanne Petri; Christian Hartmann; Antje Bornemann; Andreas Meisel; Jens A Petersen; Thomas Tousseyn; Dietmar R Thal; Jens Reimann; Peter De Jonghe; Jean-Jacques Martin; Peter Y Van den Bergh; Jörg B Schulz; Joachim Weis; Kristl G Claeys
Journal:  Orphanet J Rare Dis       Date:  2017-05-11       Impact factor: 4.123

Review 10.  Light Chain Amyloidosis.

Authors:  Paolo Milani; Giampaolo Merlini; Giovanni Palladini
Journal:  Mediterr J Hematol Infect Dis       Date:  2018-03-01       Impact factor: 2.576

View more
  1 in total

1.  Case Report: Monoclonal Gammopathies of Clinical Significance-Associated Myopathy: A Case-Based Review.

Authors:  Hongbin Yu; Du He; Qing Zhang; Bei Cao; Weiping Liu; Yu Wu
Journal:  Front Oncol       Date:  2022-07-14       Impact factor: 5.738

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.